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receiving renal replacement therapy.
Background. Acute renal failure (ARF) in the setting of end-
stage liver disease has a dismal prognosis without liver trans-
plantation. Renal replacement therapy (RRT) is a common
bridge to liver transplant despite a paucity of supportive data.
We investigated our single-center patient population to deter-
mine efficacy of RRT in liver transplant candidates with ARF.
Methods. We identified 102 liver transplant candidates re-
ceiving RRT for ARF between April 30, 1999 and January 31,
2004. Patients that had initiated RRT intra- or postoperatively
or received outpatient hemodialysis or peritoneal dialysis prior
to admission were excluded. Survival to liver transplant, short-
term mortality following liver transplant, and selected clinical
characteristics were examined.
Results. Of patients who received RRT, 35% survived to liver
transplant or discharge. Mortality was 94% in patients not re-
ceiving a liver and was associated with a higher Acute Physiolog-
ical and Chronic Health Evaluation (APACHE) II, lower mean
arterial pressure, and the use of continuous renal replacement
therapy (CRRT). Patients receiving CRRT had greater severity
of illness than those on hemodialysis. The 1-year mortality of
patients initiating RRT prior to liver transplant was 30% versus
9.7% for all other liver recipients (P < 0.0045).
Conclusion. RRT is justifiable for liver transplant candidates
with ARF. Though mortality was high, a substantial percentage
(31%) of patients survived to liver transplant. Postoperative
mortality is increased compared with all other liver transplant
recipients, but is acceptable considering the near-universal mor-
tality without transplantation.
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Nephrologists at organ transplant centers frequently
provide renal replacement therapy (RRT) to liver trans-
plant candidates with acute renal failure (ARF). These
patients are often critically ill with an extremely poor
prognosis [1–4]. Hemodynamic instability and coagu-
lopathy make RRT in these patients difficult. Experiences
in the 1970s using RRT in advanced liver disease were dis-
mal, and it was concluded that this was a futile therapy [5].
The advent of liver transplantation and continuous renal
replacement therapy (CRRT) led to renewed interest in
RRT as a supportive modality for patients awaiting liver
transplant [6–8]. Published series have reported mortality
rates as low as 25% using RRT for pretransplant ARF [7–
9]. Relatively few patients are described, and outcomes
are generally limited to those who survive to liver trans-
plant, raising issues of selection and reporting bias. The
degree of renal dysfunction when RRT is initiated is vari-
able from institution to institution and would be an addi-
tional source of bias. The largest published series reported
71% mortality for those treated with RRT pretransplant
[10]. Our goal was to investigate the survival and charac-
teristics of patients with ARF and a new requirement
for RRT while awaiting liver transplant. We chose to
study only patients who were functionally anephric and
required RRT as a bridge to transplantation. We hypoth-
esized that the efficacy of RRT in this setting has been
overestimated, and sought to reexamine the practice of
providing RRT to liver transplant candidates with ARF.
METHODS
We performed a retrospective study approved by
the Institutional Review Board of the University of
North Carolina. Using the comprehensive database of
our transplant data coordinating office, we identified all
patients on the liver or liver-kidney transplant list at
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University of North Carolina Hospitals who initiated in-
patient RRT between April 30, 1999 and January 31,
2004. We also considered patients being actively evalu-
ated for liver transplant but not yet listed at the time of
initiation of treatment. RRT was defined as intermittent
hemodialysis or any form of CRRT, including continu-
ous venovenous hemodialysis (CVVHD), hemofiltration
(CVVHF), or hemodiafiltration (CVVHDF). Individual
medical records were reviewed without blinding to pa-
tient outcomes.
Patients meeting all of the following criteria were
included: (1) diagnosis of end-stage liver disease or fulmi-
nant hepatic failure, (2) listed for, or being actively eval-
uated for orthotopic liver transplantation, liver-kidney
transplantation, or living donor liver transplantation, (3)
age 18 or older, and (4) initiation of at least one RRT
session for ARF prior to liver transplantation. Patients
were excluded for any of these criteria: (1) chronic dial-
ysis defined as any outpatient dialysis in the month prior
to admission, (2) peritoneal dialysis of any duration, or
(3) initiation of RRT intra- or postoperatively in patients
receiving a transplant.
The diagnosis of ARF and decision to initiate RRT
was determined by the consulting nephrologist. Uncuffed
double-lumen dialysis catheters were placed for vascu-
lar access. Hemodialysis was performed using Cobe 500-
HG or Gambro GFS-20 Hemophan biocompatible mem-
branes. Treatment was typically provided three times
a week for 2 to 4 hours. Target blood flow was 350
mL/min with a dialysate rate of 600 mL/min. CRRT was
performed using Prisma machines with Hospal AN69
membranes and blood flows of 100 to 140 mL/min. Re-
placement fluids utilized NaHCO3 buffer. Replacement
fluid and dialysate rates averaged 1 to 2 L/hour. Due to
theoretical advantages in liver disease, CVVHF is the
predominant modality of CRRT at our institution [11,
12]. Net ultrafiltration was determined by the consulting
nephrologist. Heparin-free protocols were generally em-
ployed because of concerns of bleeding [11].
Survival to liver transplant was the primary outcome of
the study. Clinical characteristics at time of initiation of
RRT were compared for groups of patients based on out-
come and by initial RRT modality. RRT duration was de-
fined as the length of time between the initiation of RRT
and either death, transplant, discharge from the hospital,
or documented discontinuation of RRT. The worst physi-
ologic parameters in the 24 hours prior to initiating RRT
were used to calculate Acute Physiolocial and Chronic
Health Evaluation (APACHE) II [unadjusted APACHE
II scores were calculated using the online program pro-
vided by the French Society of Anesthesia and Inten-
sive Care (www.sfar.org)] and model for end-stage liver
disease score (MELD) [MELD scores were obtained
from the United Network for Organ Sharing (UNOS)
online calculator (www.unos.org)] scores, similar to pre-
vious studies [13–15]. Oliguria was defined as <400 mL
of urine output in the 24 hours prior to RRT. Infection
was defined as a positive culture of any normally sterile
body fluid or radiographic evidence of pneumonia within
the 5-day period prior to starting RRT. Mortality of RRT
liver transplant recipients in our study was compared at 3
months and 1 year to all other liver transplant recipients
at our institution during the same period.
Statistical method
Chi-square two-sided tests were used to compare cat-
egorical variables across groups by survival status, death
versus survived to transplantation, and by type of dial-
ysis (CRRT vs. hemodialysis). To evaluate a small num-
ber of events, Fisher’s exact test was performed at alpha
level 0.05. The Wilcoxon rank-sum test evaluated dif-
ferences in continuous measures between the groups of
interest. Logistic regression identified predictors of mor-
tality. Kaplan-Meier estimates were used to generate sur-
vival curves to determine survival/failure rates at specific
time points. Statistical calculations were performed using
SAS software, version 8 (SAS, Inc., Cary, NC, USA).
RESULTS
During the study period, 286 liver transplants were per-
formed on 245 patients at our institution. We identified
159 potential subjects, and 102 patients met criteria for the
study. Fifty seven patients were excluded for the follow-
ing reasons: peritoneal dialysis (N = 2), chronic dialysis
(N = 7), intra- or postoperative RRT (N = 32), age <18
years (N = 2), not eligible for transplant list (N = 12),
never actually received RRT (N = 1), or records unavail-
able (N = 1). Overall, 31% (N = 32) of patients survived
to transplant and 4% (N = 4) were discharged without
a transplant. Sixty-five percent (N = 66) of patients died
awaiting liver transplantation. Sixty-five percent (N = 66)
of patients were initially treated with CRRT and 35%
(N = 36) received hemodialysis. Kaplan-Meier survival
curves are shown in Figure 1 with 10-day survival rate of
58% in the hemodialysis patients versus a 35% survival
rate in the CRRT patients. There were 48 (78%) deaths
in the CRRT group versus 18 (50%) in the hemodialysis
group, representing an odds ratio of 2.67 (1.14–6.23) (P =
0.02, 95% CI). The slope of the overall survival curve only
begins to plateau at 15 to 20 days after RRT initiation.
Demographic data are shown in Table 1. Most patients
were white, male, and had chronic liver disease. Fifty per-
cent of the patients had hepatitis C, alcoholic cirrhosis, or
a combination thereof. Hepatic encephalopathy (23%),
ARF (19%), and ascites (13%) were the leading admis-
sion diagnoses (data not shown). RRT was almost always
initiated in the intensive care unit. Clinical characteristics
are shown in Tables 2, 3, and 4. Hepatorenal syndrome
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Fig. 1. Kaplan-Meier plot of overall patient
survival and survival by initial renal replace-
ment therapy (RRT) modality. ∗P value is cal-
culated for comparing continuous renal re-
placement therapy (CRRT) versus hemodial-
ysis (HD).
(HRS) and acute tubular necrosis (ATN) were the most
frequent diagnoses of ARF. Volume overload was the
most cited reason for initiating RRT.
Measures of illness severity are shown in Table 3
grouped by clinical outcomes and in Table 4 grouped
by initial RRT modality. Patients who died had sig-
nificantly higher APACHE II (P = 0.005) and lower
mean arterial pressure (P = 0.04) compared to those
who survived to transplant. Patients who received CRRT
versus hemodialysis had significantly higher APACHE
II (P < 0.001), lower mean arterial pressure (P =
0.0021), lower serum creatinine (P = 0.0063), were
more likely intubated (P < 0.0001), and more likely
to have infection (P < 0.0001). No significant differ-
ences existed between either survivors and nonsurvivors
or patients receiving CRRT versus hemodialysis with
respect to median duration of RRT. Sepsis was the
leading cause of death (65.2%), followed by gas-
trointestinal bleeding/coagulopathy (10.6%), acute respi
ratory distress syndrome/pneumonia (9.2%), and intrac-
erebral event (7.6%) (data not shown). Multivariable
logistic regression modeling incorporating age, gender,
race, duration of RRT, mean arterial pressure, serum cre-
atinine, oliguria, and history of diabetes revealed that
higher mean arterial pressure was statistically associated
with a lower risk of mortality (OR = 0.97, 95% CI = 0.93,
0.99, P = 0.03) as shown in Table 6.
Survival to liver transplant in our patient cohort study is
compared with all other liver transplant recipients during
the same period in Table 5. Three-month and 1-year post-
operative mortality was significantly increased compared
to all other liver transplant recipients [15.6% vs. 4.1% (P
<0.02)] and [30% vs. 9.7% (P <0.0045)], respectively. We
further examined the subgroup of patients who initiated
RRT posttransplant (N = 28) and who were included in
the “all other liver transplant recipients” group. The mor-
tality in this subgroup of patients was similar to that of
patients initiating RRT pretransplant.
DISCUSSION
Renal failure is a common complication in liver trans-
plant candidates and predicts increased posttransplant
mortality and reduced graft survival [3, 16–23]. The high
mortality observed in this group has raised debate about
resource utilization in the care of these patients [1].
Given the shortage of organs, lengthening wait times, and
the negative association between renal insufficiency and
patient and graft survival, resource allocation issues sur-
rounding liver transplantation and renal failure are per-
tinent topics of debate [18, 21, 23]. Surprisingly, there are
little data describing the effectiveness of RRT in pretrans-
plant ARF [7–9]. Single-center reports have provided
conflicting results, with hospital mortality ranging from
0% to 71% in patients receiving RRT while awaiting liver
transplant [7–10]. Much of this variability may reflect dif-
ferences in institutional policy with regard when RRT
should be initiated. We have chosen to study only pa-
tients who were functionally anephric and required RRT
in order to survive to transplantation. Providing RRT to
these patients is challenging and fraught with complica-
tions [11, 24, 25]. Current prognostic models can help pre-
dict mortality in cirrhotics admitted to the intensive care
unit, but cannot presage which liver transplant candidate
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Table 1. Patient demographics grouped by outcomes
Died awaiting Survived to Survived to
All patients transplantation transplantation discharge without transplant
(N = 102) (N = 66) (N = 32) (N = 4) P valuea
Age (mean ± SD) 49.7 ± 10.3 50.6 ± 9.2 47.3 ± 11.7 53.5 ± 14.7 0.27
Male number (%) 65 (64) 41 (62) 23 (72) 1 (25) 0.34
White number (%) 82 (80) 53 (80) 27 (84) 2 (50) 0.63
Chronic end-stage liver disease number (%) 95 (93) 64 (97) 29 (91) 2 (50) 0.09b
Fulminant hepatic failure number (%) 7 (7) 2 (3) 3 (9) 2 (50)
Intensive care unit number (%) 91 (89) 60 (90) 28 (88) 3 (75) 0.51
Etiology of liver failure number (%)
Acetaminophen 4 (4) 1 (2) 2 (6) 1 (25)
Alcohol 7 (7) 4 (6) 3 (9) 0
Alpha1 antitrypsin 5 (5) 4 (6) 1 (3) 0
Autoimmune 5 (5) 4 (6) 1 (3) 0
Cryptogenic 8 (8) 4 (6) 4 (13) 0
Hepatitis B virus 3 (3) 3 (5) 0 0
Hepatitis C virus 24 (24) 15 (23) 9 (28) 0
Hepatitis C virus/alcohol 20 (20) 13 (20) 6 (19) 1 (25)
Nonalchoholic fatty liver disease 9 (9) 7 (11) 2 (6) 0
Primary biliary cirrhosis/primary sclerosing cholangitis 10 (10) 7 (11) 2 (6) 1 (25)
Other 7 (7) 4 (6) 2 (6) 1 (25)
aComparing patients who died versus those who survived to transplantation.
bComparing mortality rate of chronic end-stage liver disease versus fulminant hepatic failure.
Table 2. Clinical outcomes grouped by preoperative renal replacement therapy (RRT) modality and type of acute renal failure (ARF) in 102
patients
Preoperative RRT modality Type of ARF
CRRT Hemodialysis ATN HRS Prerenal Other
Died awaiting transplantation (N = 66) (%) 48 (73) 18 (50) 26 (70) 30 (61) 8 (73) 2 (40)
Survived to transplantation (N = 32) (%) 17 (26) 15 (42) 9 (24) 19 (39) 1 (9) 3 (60)
Survived to discharge without transplantation (N = 4) (%) 1 (1.5) 3 (8) 2 (6) 0 2 (18) 0
Summary 66 36 37 49 11 5
Abbreviations are: CRRT, continuous renal replacement therapy; ATN, acute tubular necrosis; HRS, hepatorenal syndrome.
with ARF will or will not survive to transplantation after
RRT is initiated [1, 4]. Is RRT an efficacious bridge to
liver transplantation given these challenges and resource
limitations?
Our results suggest an answer of yes. While the mortal-
ity observed in this cohort of patients was high, one third
survived to transplant. Liver transplantation offers the
best long-term survival rates for patients with advanced
liver failure, particularly considering the grim outcomes
of ARF without transplantation [2, 26]. A significant per-
centage of patients treated with RRT survived to liver
transplantation, despite a high acuity of illness and need
for other life-sustaining interventions. Though 65% mor-
tality is severe, it is not dissimilar to that of other critically
ill patients with ARF [10, 13, 15, 27]. Indeed, there has
been little improvement in the prognosis of ARF despite
decades of experience with RRT [15, 27, 28]. Thus, one
should not classify mortality in liver transplant candidates
receiving RRT as worse than comparably ill patients with-
out liver failure.
Once renal failure develops in advanced liver disease,
hospital mortality approaches 90%, but is less than 30%
with a liver transplant [10]. In our cohort, 94% of patients
died if they failed to receive a liver transplant, primarily
of sepsis. This follows the observation that most deaths
in patients with ARF are attributable to the underlying
disease process and not ARF per se. Similarly, it would be
an oversimplification to conclude that survival to trans-
plant in our cohort was a result of RRT alone. We cannot
identify those patients who survived because of RRT and
those who would have survived to liver transplant without
RRT. Patients who survived to transplant had relatively
less severe indices of illness and may have been healthier
at the onset of RRT. Other factors, such as the effect of
timing of initiation of RRT and cointerventions were not
examined. It is safe to assume that the improved survival
seen in patients who received a liver was attributable pri-
marily to the reversal of liver failure with transplantation.
We acknowledge the limitations of RRT, but its contribu-
tion as a bridge to liver transplant is clinically important.
Candidates who survived may have otherwise died from
electrolyte disturbances or uremic complications or been
too volume overloaded to undergo transplantation. Our
findings reinforce the notion that once ARF develops,
liver transplant candidates will likely not survive unless
they are transplanted.
Our study raises the issue of the relationship between
the duration of RRT and survival to liver transplant.
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Table 3. Clinical characteristics grouped by outcomesa in 102 patients
Died awaiting Survived to Survived to
All patients transplantation transplantation discharged without transplantation
(N = 102) (N = 66) (N = 32) (N = 4) P valueb
RRT indication (%)
Acidosis 10 (10) 7 (11) 3 (10) 0
Hyperkalemia 7 (7) 2 (3) 4 (12) 1 (25)
Uremia 7 (7) 4 (6) 3 (10) 0
Volume 54 (53) 38 (58) 17 (53) 0
Multiple 21 (21) 14 (21) 4 (12) 3 (75)
Not specified 3 (2) 1 (3) 2 (6) 0
APACHE II 28.7 ± 7.6 30.2 ± 7.3 25.9 ± 7.7 26.5 ± 6.2 0.005
RRT durationc 6.0 (3.0-12.0) 6.0 (3.0-10.0) 9.5 (3.0-18.0) 7.0 (2.5-45.0) 0.08
Model for end-stage renal disease 38.9 ± 8.8 39.5 ± 7.9 38.5 ± 10.2 32.3 ± 10.2 0.59
Mean arterial pressure mm Hg 61.3 ± 14.5 58.7 ± 13.3 64.5 ± 13.6 77.4 ± 26.2 0.04
Creatinine mg/dL 4.2 ± 2.0 4.1 ± 1.9 4.4 ± 2.1 4.7 ± 2.7 0.50
Oliguriad 56 (55) 38 (58) 18 (56) 0 0.90
Infectione 44 (43) 34 (52) 10 (31) 0 0.06
Intubated 42 (41) 32 (48) 9 (28) 1 (25) 0.06
Vasopressors 46 (45) 34 (52) 12 (38) 0 0.19
Abbreviations are: RRT, renal replacement therapy; APACHE II, Acute Physiological and Chronic Health Evaluation.
aData presented as number (%) or mean ± SD unless otherwise specified.
bComparing patients who died versus those who survived to transplantation.
cMedian number of days (25% to 75% interquartile range).
d<400 mL urine output 24 hours prior to RRT.
ePositive culture of normally sterile body fluid or radiographic evidence of pneumonia in the 5 days prior to RRT.
Table 4. Clinical characteristics by initial preoperative renal replacement therapy (RRT) modalitya
CRRT (N = 66) Hemodialysis (N = 36) P valueb
Hospital mortalityc (%) 48 (73) 18 (50) 0.02
RRT durationd 6.0 (3.0-11.0) 7.5 (3.0-15.0) 0.28
APACHE II 31.2 ± 7.2 24.1 ± 6.1 <0.001
Model for end-stage renal disease 38.5 ± 8.7 39.6 ± 9.0 0.44
Mean arterial pressure mm Hg 58.0 ± 13.5 67.3 ± 14.4 0.0021
Creatinine mg/dL 4.0 ± 2.2 4.7 ± 1.4 0.0063
Oliguriae (%) 36 (55) 20 (56) 0.92
Infectionf (%) 27 (41) 17 (47) 0.54
Intubated (%) 39 (59) 3 (8) <0.0001
Vasopressors (%) 41 (62) 5 (14) <0.0001
Abbreviations are: RRT, renal replacement therapy; APACHE II, Acute Physiological and Chronic Health Evaluation; CRRT, chronic renal replacement therapy.
aData presented as number (%) or mean ± SD unless otherwise specified.
bComparing CRRT versus hemodialysis.
cCensored at time of transplant for those who received an organ but subsequently died.
dMedian number of days (25% to 75% interquartile range).
e<400 mL urine output 24 hours prior to RRT.
fPositive culture of normally sterile body fluid or radiographic evidence of pneumonia in the 5 days prior to RRT.
There was a steep decline in survival observed once RRT
began. Approximately one half of patients died in the
first 7 days after initiating RRT, though the overall sur-
vival curve did not plateau until 15 to 20 days. Possi-
bly, some patients who died after initiating RRT were
so sick they would have died regardless of whether or
not they received treatment. Interestingly, though no sig-
nificant differences in the median duration of RRT were
observed between groups or between RRT modalities, a
trend of increased survival and longer RRT duration was
seen. This probably reflects two factors: the longer a pa-
tient survived on RRT, the better the chances an organ
would become available, and patients who lived longer
may have been less ill than nonsurvivors. Thus, duration
of RRT cannot predict which liver transplant candidates
will likely survive to organ transplantation. Our multi-
variate regression model demonstrates no independent
relationship between RRT duration and survival. This
finding may be particularly important in the setting of lim-
ited resources where nephrologists might consider with-
drawing prolonged RRT in a critically ill liver transplant
candidate awaiting an organ.
The retrospective nature of our study imposed limita-
tions, and efforts were made to minimize the bias. The
study criteria and outcome measures were established a
priori, and we limited the number of variables in our logis-
tic regression model. When outcomes were clearly con-
founded, we avoided statistical analysis or interpretation.
By including all patients receiving RRT while awaiting
liver transplant, and not just those who survived to liver
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Table 5. Survival for pretransplant renal replacement therapy (RRT) liver recipients versus all other liver recipients
Initiated RRT All other liver Initiated RRT
pretransplant transplant recipients posttransplanta
(N = 32) (N = 220) (N = 28) P value
3-month mortality 5/32 (15.6)b 9/220 (4.1) 6/28 (21.4)f 0.02
1-year mortality 9/30 (30)c,d 20/206 (9.7)e 9/27 (33.3)g,h 0.0045
aSubgroup of all other liver transplant recipients not in primary study cohort.
bP < 0.02 versus all other liver transplant recipients.
cP < 0.0045 versus all other liver transplant recipients.
dData missing for twp patients.
eData missing for 14 patients.
fP = nonsignificant versus pre-transplant RRT group.
gP = nonsignificant versus pretransplant RRT group.
hData missing for one patient.
Table 6. Multivariate analysis of clinical parameters as predictors of
survival
Parameters Odds Ratio 95% CI P value
Age 1.03 (0.98, 1.08) 0.26
Gender male vs. female 1.13 (0.43, 2.97) 0.82
Race nonwhite vs. white 1.37 (0.41, 4.57) 0.59
Mean arterial pressure 0.96a (0.93, 0.99) 0.03a
Creatinine 0.89 (0.69, 1.14) 0.38
Oliguria yes vs. no 1.02 (0.38, 2.74) 0.96
Diabetes yes vs. no 1.07 (0.37, 3.08) 0.96
RRT duration 0.99 (0.96, 1.03) 0.70
aStatistically significant using two-sided with alpha level 0.05.
transplantation, we attempted to reduce reporting bias,
which could lead to an underestimate of mortality.
Our patients are likely similar to those encountered at
other modern transplant centers. To our knowledge, this
is the largest single cohort described thus far of liver trans-
plant candidates receiving RRT for ARF while awaiting
transplantation. Some of the apparent success in earlier
studies may have been the result of selection or publi-
cation bias, where only healthier patients received RRT
or positive experiences were published. In an earlier re-
port, a small but significant increase from 1.8% to 3.9%
of liver transplant recipients requiring preoperative RRT
was observed with the advent of CRRT [9]. By compar-
ison, 32/245 (13.1%) of liver transplant recipients at our
institution received RRT for ARF preoperatively. As re-
ported earlier, the acuity of illness encountered in liver
transplant candidates has increased, with 89% of our pa-
tients initiating RRT in the intensive care unit [9].
We excluded seven patients who were on the trans-
plant list, but who had previously undergone outpatient
hemodialysis. None of these patients had been diagnosed
with HRS. Four of these subjects had biopsy-proven in-
trinsic causes of renal failure (membranous nephropa-
thy, focal and segmental glomerulosclerosis, and IgA
nephropathy) that in some cases predated their end-stage
liver disease. Patients stable enough to receive outpatient
treatment are clinically distinct from patients who de-
velop new-onset ARF requiring RRT. Inclusion of these
individuals could have biased our results toward more
favorable outcomes.
The high APACHE II and MELD scores observed
illustrate the severity of illness in our cohort. The
APACHE II score has been shown to have good prog-
nostic value when applied to patients requiring RRT
and those with cirrhosis [4, 13–15, 29]. The overall mean
APACHE II score of 28.7 correlated well with the ob-
served 65% mortality rate. The mean APACHE II was
significantly higher in patients who died on RRT com-
pared with eventual transplant recipients, 30.2 vs. 25.9
(P < 0.005). The MELD score estimates a patient’s risk
of dying while awaiting liver transplantation, and has
been used by UNOS and organ procurement organiza-
tions since February 2002 to prioritize liver allocation.
The mean overall MELD score was 38.9, and was not
statistically different among survivors and nonsurvivors.
Higher MELD scores also predict death after liver trans-
plant, and the values in our cohort were extremely high by
national standards [3, 22, 23, 30–33]. Because the MELD
score was not utilized for organ prioritization in earlier
members of our cohort and the impact of RRT on survival
of later patients was confounded by the MELD score’s ef-
fect on organ allocation (i.e., survival correlated in large
part with getting a liver), we did not include it in our
regression model. Ongoing controversy and debate re-
mains about the MELD score’s impact on overall organ
resources and patient survival posttransplant [3, 22, 23,
30, 33–35].
Importantly, the MELD calculation and renal function
deserves mention. Given that the mean serum creatinine
of patients initiating RRT was 4.2 mg/dL, it is unlikely that
the decision to provide RRT would have added much
weight to the MELD calculation (which considers two
RRT treatments in the previous week equivalent to a
serum creatinine of 4.0 mg/dL). Considering this, and with
average MELD scores already near the UNOS-defined
maximum of 40 and substantially higher than the national
mean of 23.9, it seems unlikely that initiating RRT im-
pacted significantly on organ allocation [33, 35]. How-
ever, the dramatic increase in mortality observed after
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RRT is initiated and the strong correlation between liver
transplant and survival, indicates a discrepancy between
the weight given to ARF requiring RRT in the MELD cal-
culation and clinical observations. Simply, once a critically
ill liver transplant candidate develops ARF and initiates
RRT, our data suggest that survival depends on whether
or not they rapidly receive a liver transplant, and that
the current liver allocation scheme may not adequately
account for this.
Because the definition of ARF was unspecified and
there was no standardized criteria for initiating RRT, we
accepted the diagnosis of ARF and the decision to initi-
ate RRT without interpretation or proof of veracity [27,
36]. The percentage of patients with HRS (48%) was rel-
atively high in our study, but similar to previous studies
[12, 37]. ATN is often a consequence of prolonged HRS
and is frequently difficult to distinguish from HRS in the
oliguric patient. As a result, ATN may be misclassified
as HRS, even in centers experienced in liver failure [3,
17, 25, 37]. Prerenal failure, HRS, and ATN all lay on the
same continuum of ARF. The intense, irreversible renal
vasoconstriction that characterizes HRS represents the
most extreme form of prerenal failure, while ATN can
result from prolonged prerenal failure, HRS, or numer-
ous insults encountered in the intensive care unit [3, 17,
20, 25]. Diagnostic percutaneous renal biopsy is usually
not feasible in critically ill coagulopathic patients [3, 17].
Due to the retrospective nature of the study, we did not
examine outcomes based on these classifications. Regard-
less of etiology, ARF in advanced liver disease still has a
poor prognosis, with mortality rates exceeding 90% [1–3,
37].
Our study was not intended to demonstrate the superi-
ority of a particular RRT modality or to examine the dose
or delivery of RRT. There is substantial uncertainty and
conflicting data regarding the optimal modality, prescrip-
tion, and timing of initiation of RRT in ARF; and no such
information exists for patients with advanced liver failure
[3, 7, 9, 10, 14, 24, 25, 27, 32, 38]. CRRT has been advo-
cated for use in liver disease due to better hemodynamic
stability and improved physiologic parameters [11, 12].
Prospective data are scant, and trials have actually shown
increased mortality associated with CRRT in liver disease
[9, 10, 14]. Our cohort clearly exhibited decreased sur-
vival in patients treated initially with CRRT. The impli-
cation that CRRT is inferior to hemodialysis requires fur-
ther examination. Patients who initially received CRRT
were much sicker, with higher mean APACHE II scores
(31.2 v. 24.1), lower mean mean arterial pressure (58 vs.
67.3 mm Hg), and were more likely intubated (59% vs.
8%) and on vasopressors (62% vs. 14%). Thus, the choice
of modality seemed to be largely predicated on severity
of illness, with hemodynamic instability precluding stan-
dard hemodialysis and necessitating the default use of
CRRT. Only 1/48 (2%) of patients who died after ini-
tiating RRT with CRRT switched to hemodialysis, while
8/18 (44%) of patients who died after initiating RRT with
hemodialysis switched to CRRT (data not shown). Thus,
patients sick enough to require CRRT at onset stayed on
CRRT and those healthy enough to start hemodialysis
frequently got sicker and later required CRRT. Numer-
ous interruptions of CRRT, nonsteady-state physiologic
conditions, and logistic issues affecting the availability
of RRT make further analysis of RRT dose problem-
atic. The optimal prescribed dose of RRT in ARF will be
studied in an upcoming multicenter prospective trial [Pa-
ganini E, Palevsky P, National Kidney Foundation 2004
Clinical Meetings, Chicago, IL, USA] and is currently un-
known.
Two traditional prognostic markers, serum creatinine
and oliguria, were not helpful in our study. Creatinine
and percentage of oliguric patients was not different be-
tween survivors and nonsurvivors. An unexpected find-
ing was the higher mean serum creatinine measurements
in the hemodialysis (4.7 mg/dL) versus the CRRT group
(4.0 mg/dL). Survival in numerous studies has correlated
with both pre- and post-liver transplant serum creatinine
[21, 24, 25, 35]. Differences in creatinine metabolism and
metabolism lead to overestimates of glomerular filtration
rate (GFR) in liver disease, though mean levels greater
than 4.0 mg/dL imply profound reductions in GFR in all
subgroups in our study [17, 36]. Thus, the observed dif-
ference in creatinine is probably not clinically significant.
Another unexpected finding was that oliguric patients
did not have worse outcomes than those with nonoliguric
ARF. Whether this lack of difference is because some of
the patients who were initially nonoliguric later became
oliguric is unclear.
Patients who initiated RRT preoperatively and met our
study criteria had significantly worse 3-month and 1-year
survival compared to all other liver transplant recipients
at our institution. This is consistent with previous studies
linking pretransplant renal failure and/or need for pre-
transplant RRT with poorer outcomes following success-
ful liver transplant [10, 16, 18, 21, 22, 28]. Interestingly,
when we identified patients who were not in our pre-
transplant RRT cohort who had initiated RRT for post-
transplant renal failure, it became clear that this subgroup
accounted for most of the mortality among all other liver
transplant recipients at our center. Again, this reinforces
data that associates posttransplant RRT and worse re-
nal function with worse outcomes [9, 10, 19, 31, 39]. In a
larger sense, the 1-year 70% survival rate of liver trans-
plant recipients receiving pretransplant RRT compared
to 4% hospital survival without liver transplant reflects a
tremendous improvement in mortality.
In our regression model, mean arterial pressure was
the sole independent predictor of mortality. Patients with
greater hemodynamic instability were more likely to be
placed on CRRT. It appears that the choice of CRRT
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over hemodialysis was determined largely by severity
of illness and low mean arterial pressure. Though ex-
isting studies have not demonstrated a survival advan-
tage of CRRT in liver failure, our nephrologists likely
chose CRRT more frequently due to severe hypoten-
sion. There is growing interest in short daily hemodial-
ysis and slow, prolonged, low-efficiency dialysis (SLED)
as better tolerated alternatives to triweekly hemodialyis
or CRRT. So far, only one randomized controlled trial
exists demonstrating an advantage of daily over inter-
mittent hemodialysis for ARF [40]. While there are no
data yet to support these practices in liver transplant can-
didates, they do have theoretic advantages and deserve
further study. The molecular adsorbent recirculating sys-
tem (MARS) and more recently, simultaneous albumin
dialysis and high-flux hemodialysis in patients with ad-
vanced liver failure have attracted recent interest [41–43].
Though results are promising, these systems are expen-
sive and not available at many transplant centers. Wider
experience is needed to determine the role of MARS and
other nonconventional dialytic modalities in managing
the liver transplant candidate with ARF.
Our study was not designed to investigate the role of
combined liver-kidney transplant. Only four patients in
our cohort received liver-kidney transplant, with 75% 1-
year survival. These small numbers preclude any mean-
ingful conclusions, though this topic is currently of great
interest and should be further investigated.
CONCLUSION
ARF requiring RRT in patients with liver failure is a
strong predictor of mortality both pre- (65%) and post-
(30%) liver transplantation. Despite this, many patients
(>30% in this series) survive to liver transplantation
with the support of RRT. These patients, with average
APACHE II scores of 29 and average MELD scores of
39 in our series, have an acceptable 70% 1-year survival
posttransplantation. Although sicker patients clearly suf-
fer higher mortality, RRT should not be withheld in a
liver transplant candidate because of the severity of ill-
ness alone. With lengthening wait times and organ short-
ages, the incidence and cumulative burden of ARF in
patients with advanced liver disease is likely to increase.
Our data demonstrate that once a patient initiates RRT,
they have a limited and rapidly shrinking opportunity for
survival: liver transplant.
Unfortunately, the solution is not within ready grasp
due to geographic disparities in access to organs as pri-
oritized by MELD scores. Differences in geographic al-
location of livers based upon local organ procurement
agencies have resulted in a disparate number of organs
being allocated to centers with smaller waiting lists and
less severely ill candidates [33]. It is imperative to pro-
vide our patients with a liver graft in a more reasonable
period of time after initiating RRT. This is another call to
implement the 1999 Institute of Medicine’s recommen-
dation to establish organ allocation areas serving a pop-
ulation base of at least 9 million people [44]. Until these
changes are made, it is the responsibility of the nephrolo-
gist to initiate RRT promptly for ARF in liver transplant
candidates and to provide supportive care until an organ
becomes available.
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